Profile data is unavailable for this security.
About the company
Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).
- Revenue in USD (TTM)300.00k
- Net income in USD-13.15m
- Incorporated1998
- Employees29.00
- LocationYield10 Bioscience Inc19 Presidential Way Ste 201WOBURN 01801-1184United StatesUSA
- Phone+1 (617) 583-1700
- Fax+1 (302) 655-5049
- Websitehttps://www.yield10bio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GRI Bio Inc | 0.00 | -12.77m | 760.76k | 4.00 | -- | 0.1107 | -- | -- | -349.68 | -349.68 | 0.00 | 11.38 | 0.00 | -- | -- | 0.00 | -382.23 | -192.93 | -869.57 | -353.99 | -- | -- | -- | -37,650.49 | -- | -16.80 | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
International Stem Cell Corp | 7.83m | -327.00k | 784.43k | 29.00 | -- | -- | -- | 0.1002 | -0.0409 | -0.0409 | 0.9785 | 0.0045 | 1.46 | 2.53 | 11.87 | 270,069.00 | -5.81 | -29.22 | -68.13 | -73.82 | 58.58 | 59.49 | -3.97 | -21.01 | 0.4672 | -6.06 | 0.9898 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
Meso Numismatics Inc | 2.44m | -10.10m | 809.61k | 1.00 | -- | -- | -- | 0.3317 | -0.8113 | -0.8113 | 0.1959 | -1.90 | 0.438 | -- | 33.37 | -- | -181.33 | -192.08 | -- | -- | 69.97 | 60.24 | -413.98 | -821.49 | -- | -0.1106 | -- | -- | 57.49 | 116.97 | -76.03 | -- | 149.35 | -- |
NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 944.10k | 24.00 | -- | -- | -- | 0.0663 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Yield10 Bioscience Inc | 300.00k | -13.15m | 1.04m | 29.00 | -- | -- | -- | 3.47 | -146.30 | -146.30 | 1.06 | -123.90 | 0.0627 | -- | -- | 10,344.83 | -274.51 | -91.26 | -2,396.54 | -108.09 | -- | -- | -4,381.67 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
VG Life Sciences Inc | 0.00 | -4.30m | 1.05m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
Herborium Group, Inc. | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
GlobeStar Therapeutics Corp | 0.00 | -1.98m | 1.16m | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
LadRx Corp | 0.00 | 1.66m | 1.23m | 2.00 | 0.7201 | 3.56 | 0.7341 | -- | 3.44 | 3.44 | 0.00 | 0.6973 | 0.00 | -- | -- | 0.00 | 96.28 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
Seelos Therapeutics Inc | 1.97m | -27.12m | 1.26m | 10.00 | -- | -- | -- | 0.6374 | -44.59 | -44.59 | 2.16 | -17.36 | 0.1449 | -- | 2.24 | 131,600.00 | -198.99 | -180.05 | -- | -386.76 | -- | -- | -1,373.61 | -9,612.88 | -- | -- | -- | -- | -- | -- | 48.48 | -- | -- | -- |
Tron Pharmaceuticals Inc | 1.01m | -549.47k | 1.28m | 50.00 | -- | -- | -- | 1.27 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Mar 2024 | 38.58k | 6.00% |
G1 Execution Services LLCas of 31 Mar 2024 | 3.27k | 0.51% |
BBVA Asset Management SA SGIICas of 31 Dec 2023 | 2.51k | 0.39% |
Cutter & Co. Brokerage, Inc. (Investment Management)as of 31 Mar 2024 | 2.08k | 0.32% |
UBS Securities LLCas of 31 Mar 2024 | 797.00 | 0.12% |
Birchview Capital LPas of 31 Mar 2024 | 781.00 | 0.12% |
Two Sigma Securities LLCas of 31 Mar 2024 | 681.00 | 0.11% |
XTX Markets LLCas of 31 Mar 2024 | 640.00 | 0.10% |
Grand Wealth Management LLCas of 31 Mar 2024 | 507.00 | 0.08% |
Tower Research Capital LLCas of 31 Mar 2024 | 444.00 | 0.07% |